Business Context and Reporting Period
Company: Arvinas, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2021
Reporting Period: Immediate event reporting regarding a material definitive agreement entered into on July 21, 2021.
Arvinas, Inc. announced a strategic Collaboration Agreement with Pfizer Inc. regarding the development and commercialization of Arvinas's proprietary compound ARV-471. This filing also details a concurrent equity transaction and investor agreement.
Key Financial Metrics and Transaction Terms
The filing outlines a significant capital infusion and partnership structure rather than standard quarterly operating results.
- Upfront Payment: Pfizer to pay Arvinas $650 million upon closing.
- Equity Investment: Pfizer to purchase approximately $350 million of Arvinas common stock (3,457,815 shares at $101.22 per share).
- Contingent Milestones: Arvinas is eligible for up to an additional $1.4 billion in regulatory and sales-based milestones ($400 million specifically for marketing approvals).
- Cost Sharing: Development costs and commercialization profits/losses (outside specific regions) are shared 50/50.
- Liquidity Estimate: Arvinas estimates pro forma cash, cash equivalents, and marketable securities of approximately $1.6 billion as of June 30, 2021, assuming the transaction closes. Actual estimated cash as of June 30, 2021, is approximately $605 million.
Material Changes and Agreements
The primary material change is the entry into three definitive agreements on July 21, 2021:
- Collaboration Agreement: Grants Pfizer worldwide co-exclusive rights to ARV-471. Arvinas retains the marketing authorization holder role in the U.S., while Pfizer holds it outside the U.S.
- Stock Purchase Agreement: Establishes the $350 million equity purchase. Closing is subject to Hart-Scott Rodino (HSR) antitrust clearance. A termination fee of $40 million is payable by Pfizer if the deal fails to close due to HSR clearance issues by the termination date.
- Investor Agreement: Imposes a two-year standstill restriction on Pfizer regarding the acquisition of additional equity or control actions without Arvinas's approval.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The transaction is expected to significantly enhance Arvinas's liquidity and accelerate the development of ARV-471. The company plans to announce updates on its development plan for ARV-471 and other clinical programs on July 22, 2021.
Risks and Contingencies:
- Closing Conditions: The equity transaction and collaboration are subject to HSR clearance and other customary closing conditions.
- Termination: Pfizer may terminate the collaboration for convenience. Either party may terminate for uncured material breach or insolvency.
- Forward-Looking Statements: The filing contains substantial risks regarding the ability to successfully conduct clinical trials, obtain marketing approval, and commercialize ARV-471 on current timelines.
- Financial Estimates: The pro forma cash position of $1.6 billion is preliminary and unaudited; actual figures may differ materially upon final closing procedures.
Investor Verification Checklist
- Verify the receipt of HSR antitrust clearance required for the closing of the $350 million equity transaction.
- Confirm the final closing date of the Collaboration Agreement and the receipt of the $650 million upfront payment.
- Review the specific terms of the 50/50 profit and loss sharing, particularly regarding exceptions and regional commercialization rights.
- Monitor the preliminary cash estimate of $1.6 billion against the final audited financial statements following the transaction close.
- Assess the impact of the two-year standstill restrictions on Pfizer's ability to influence company governance or acquire further equity.